Abstract YO35
Case summary
Background - Epidermal growth factor receptors have been commonly associated with rash, diarrhoea and nail changes
Case details - A 57 year female, a known case of EGFR positive metastatic Adenocarcinoma of the lung with Pleural, liver and bone involvement, who had been started on Gefitinib 250 mg once daily upfront eight months ago presented with complaints of involuntary movements involving the jaw and neck since the past 15 days. She had to take resort to clenching her teeth tightly in an attempt to control the movements which interfered with mastication and activities of daily living. They were not suppressed during sleep. She also reported bite marks on the lips and tongue along with mucosal ulcerations. The movements did not involve the upper or lower extremity. There was a positive history of reduced oral intake, however she did not report any difficulty upon swallowing. There were no signs of intracranial metastasis. She had also undergone ICD insertion for right sided malignant pleural effusion and had received palliative radiotherapy for vertebral metastasis (L1-L5). CT scan done at the time of presentation was suggestive of a right hilar mass with pleural, hepatic and bone involvement. Response assessment CT (performed after seven months of upfront EGFR Tyrosine kinase inhibitor) was suggestive of significant interval change in the Lung mass with reduction in size and number of liver lesions. MRI performed after development of abnormal movements was not suggestive of any intracranial pathology. The patient had been started on Gabapentin for targeting the neuropathic component of her bone pain, so a diagnosis of Gabapentinoid induced movement disorder was also considered. She was referred to the medical oncologist, where her EGFR Tyrosine kinase inhibitor was discontinued.
Discussion - She reported an improvement in her symptoms after the discontinuation of the Gefitinib (small cell transformation was suspected). A WHO-UMC category of possible/likely causation and score of 3 was obtained on Naranjo’s algorithm (possible Adverse drug reaction). Gabapentinoids were continued on the subsequent visit. This is one of the first reports of a movement disorder due to a EGFR tyrosine kinase inhibitor.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract